Thyrocare Technologies Share Price Today | Stock Price & Thyrocare Technologies Share Screener
As of October 5, 2026, the live Thyrocare Technologies share price (NSE: THYROCARE) is ₹542.05 on NSE and ₹540.95 on BSE, up 1.58% from the previous close, with shares trading between ₹532.15 and ₹544.80 in today's trading session, and a 52-week range of ₹349.55–₹1,591.90. Check THYROCARE annual price range for the annual price range and momentum. Use the Thyrocare Technologies stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Thyrocare Technologies opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹245 and net income of ₹51, with EBITDA of ₹82, an operating margin of 32.0% and a profit margin of 20.8%.
Thyrocare Technologies Share Price Chart
Track the current stock price of Thyrocare Technologies with an interactive chart. Analyse THYROCARE share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Thyrocare Technologies stock quote in one place.
The quote of ₹542.05 sits between the 52-week low of ₹349.55 and the 52-week high of ₹1,591.90, and the latest session moved 1.58% from the previous close.
Thyrocare Technologies Company Profile - Fundamental Screener
Screen Thyrocare Technologies company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for THYROCARE shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare Services sector and the Healthcare Service Provider industry, and it trades under ISIN INE594H01019.
Company Details
Classification
Identifiers and Leadership
Thyrocare Technologies Balance Sheet Screener
Screen THYROCARE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹747, up from ₹693 in 2025.
Latest statistics put total assets at ₹747 and shareholder funds at ₹586, with a leverage ratio of 0.07.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 747 | 693 | 644 | 633 | 608 | 546 | 471 | 475 | 479 | 438 |
| Current Assets | 372 | 338 | 279 | 273 | 270 | 240 | 152 | 136 | 142 | 150 |
| Fixed Assets | 317 | 297 | 306 | 294 | 285 | 253 | 269 | 294 | 299 | 259 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 51 | 24 | 26 | 20 | 17 | 23 | 23 | 19 | 15 | 12 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 586 | 547 | 528 | 535 | 527 | 427 | 367 | 435 | 443 | 408 |
| Share Capital | 159 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 54 | 54 |
| Reserves & Surplus | 354 | 439 | 440 | 463 | 474 | 374 | 314 | 382 | 390 | 354 |
Thyrocare Technologies Income Statement Screener - Profit & Revenue Analysis
Screen Thyrocare Technologies income statement and profit fundamentals. Analyze THYROCARE quarterly results. Thyrocare Technologies reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Jun, revenue was ₹245 and net profit was ₹51, equal to earnings per unit of ₹3.23, at an operating margin of 32%.
In that period expenses were ₹163, interest cost ₹1 and tax ₹17. The next period listed, 2026-Mar, shows revenue of ₹229 and net profit of ₹49.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 245 | 229 | 201 | 220 | 198 | 192 | 170 | 180 | 161 | 158 | 138 | 151 | 136 | 140 | 131 |
| Expenses | 163 | 149 | 144 | 145 | 135 | 130 | 124 | 129 | 115 | 121 | 103 | 111 | 100 | 111 | 100 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 82 | 80 | 57 | 75 | 63 | 62 | 46 | 51 | 46 | 37 | 35 | 40 | 36 | 29 | 31 |
| Operating Profit % | 32.00% | 34.00% | 26.00% | 33.00% | 30.00% | 30.00% | 25.00% | 27.00% | 27.00% | 22.00% | 23.00% | 25.00% | 26.00% | 18.00% | 22.00% |
| Depreciation | 13 | 14 | 22 | 12 | 11 | 14 | 17 | 13 | 11 | 13 | 14 | 11 | 10 | 11 | 10 |
| Interest | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 68 | 64 | 35 | 63 | 51 | 47 | 28 | 37 | 34 | 23 | 20 | 28 | 25 | 17 | 20 |
| Tax | 17 | 16 | 7 | 15 | 12 | 26 | 9 | 10 | 10 | 6 | 5 | 8 | 8 | 5 | 5 |
| Net Profit | 51 | 49 | 28 | 48 | 38 | 22 | 19 | 26 | 24 | 17 | 15 | 20 | 17 | 13 | 15 |
| EPS | 3.23 | 2.99 | 1.82 | 9.05 | 7.35 | 4.17 | 3.58 | 4.99 | 4.52 | 3.54 | 2.78 | 3.84 | 3.26 | 2.36 | 2.78 |
Thyrocare Technologies Cash Flow Screener - Liquidity Fundamentals
Screen THYROCARE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹213, and net cash flow was an inflow of ₹21.
Over the same period, investing activities used ₹23 and financing activities used ₹170.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 213 | 191 | 168 | 129 | 113 | 115 | 168 | 100 | 107 | 90 |
| Investing Activities | -23 | -53 | -91 | -39 | -24 | -49 | 1 | -12 | -43 | -42 |
Financing and Net Cash | ||||||||||
| Financing Activities | -170 | -130 | -85 | -86 | -89 | -62 | -165 | -94 | -64 | -49 |
| Net Cash Flow | 21 | 8 | -9 | 4 | 0 | 5 | 4 | -5 | 0 | -1 |
Thyrocare Technologies Shareholding Pattern Screener
See Thyrocare Technologies shareholding pattern with promoter, FII, and DII holdings. Check Thyrocare Technologies promoter holding and ownership changes for THYROCARE on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 60.92%, foreign institutions 5.44%, domestic institutions 20.92% and the public 10.35%, spread across 73,064 shareholders.
The shareholder count was 73,064 in 2026-Jun, compared with 73,377 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 60.92% | 60.92% | 60.93% | 71.06% | 71.06% | 71.06% | 71.06% | 71.11% |
Institutional Investors | ||||||||
| FII Holding | 5.44% | 5.37% | 4.95% | 4.85% | 3.23% | 2.41% | 2.77% | 1.93% |
| DII Holding | 20.92% | 20.99% | 20.51% | 13.47% | 14.54% | 14.97% | 14.67% | 14.80% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 10.35% | 10.18% | 10.88% | 8.19% | 8.94% | 9.21% | 9.16% | 9.78% |
| Other Holding | 2.36% | 2.53% | 2.73% | 2.43% | 2.23% | 2.36% | 2.33% | 2.38% |
| Shareholder Count | 73,064 | 73,377 | 77,969 | 54,142 | 54,566 | 57,403 | 56,666 | 59,377 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Thyrocare Technologies. Thyrocare Technologies dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹14.00 per unit for 2026-March, a yield of 2.55%, compared with ₹21.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹14.00, ₹21.00 and ₹18.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹14.00 | 2.55% |
| 2025-March | ₹21.00 | 6.01% |
| 2024-March | ₹18.00 | 7.95% |
| 2023-March | ₹18.00 | 9.15% |
| 2022-March | ₹15.00 | 10.47% |
| 2021-March | ₹25.00 | 9.67% |
| 2020-March | ₹5.00 | 1.66% |
| 2019-March | ₹20.00 | 12.08% |
| 2018-March | ₹10.00 | 5.62% |
| 2017-March | ₹10.00 | 5.03% |
Thyrocare Technologies Stock Index Membership - Nifty & Sensex
See which indices include Thyrocare Technologies stock. Check THYROCARE index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 3 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP.
Complete Index List
Thyrocare Technologies Market Events Screener - Corporate Actions
Get Thyrocare Technologies corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Thyrocare Technologies stock events that may affect THYROCARE share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated July 23, 2026, with a record date of July 23, 2026.
It is followed by Annual General Meeting dated June 30, 2026 and Dividend dated June 23, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-07-23 | 2026-07-23 | Quarterly Result Announcement | NA | 5.17% |
| 2026-06-30 | 2026-06-30 | Annual General Meeting | NA | 0.58% |
| 2026-06-23 | 2026-06-23 | Dividend | ₹ 7.00 /share | 18.26% |
| 2026-05-07 | 2026-05-07 | Quarterly Result Announcement | NA | 13.28% |
| 2026-01-28 | 2026-01-28 | Quarterly Result Announcement | NA | -4.81% |
| 2025-11-28 | 2025-11-28 | Bonus | 2:1 | -5.76% |
| 2025-10-24 | 2025-10-24 | Dividend | ₹ 7.00 /share | -0.66% |
| 2025-10-14 | 2025-10-14 | Quarterly Result Announcement | NA | 7.05% |
| 2025-07-31 | 2025-07-31 | Annual General Meeting | NA | 27.09% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 21.00 /share | 68.16% |
| 2025-07-23 | 2025-07-23 | Quarterly Result Announcement | NA | 2.06% |
| 2025-04-23 | 2025-04-23 | Quarterly Result Announcement | NA | 13.10% |
| 2025-01-23 | 2025-01-23 | Quarterly Result Announcement | NA | -2.22% |
| 2024-10-23 | 2024-10-23 | Quarterly Result Announcement | NA | 7.33% |
| 2024-08-23 | 2024-08-23 | Annual General Meeting | NA | 8.95% |
Thyrocare Technologies Competitors Screener - Peer Stocks Comparison
Screen THYROCARE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare Services sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | 32,637 | 59.65 | 2,864 | 12.11% | 510 | 56.98 |
| Vijaya Diagnostic Centre | 15,381 | 82.40 | 835 | 19.34% | 173 | 51.12 |
| Metropolis Healthcare | 11,708 | 58.51 | 1,671 | 24.15% | 191 | 45.27 |
| Thyrocare Technologies | 8,738 | 49.67 | 846 | 20.48% | 163 | 40.92 |
| Nephrocare Health Services | 6,707 | 79.69 | 1,023 | 32.93% | 77 | 37.77 |
| Suraksha Diagnostic | 1,830 | 51.63 | 314 | 22.55% | 31 | 61.81 |
| Krsnaa Diagnostics | 1,763 | 17.83 | 816 | 9.90% | 101 | 41.10 |
| 3B BlackBio DX | 1,367 | 24.11 | 142 | 27.17% | 61 | 66.56 |
| One Global Service Provider | 1,052 | 14.38 | 499 | 237.48% | 70 | 49.71 |
| Health X Platform | 890 | -34.21 | 1,319 | 12.68% | -3 | 38.00 |
Thyrocare Technologies Company Announcements - News & Reports Screener
Screen THYROCARE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated .
The next most recent announcements are dated October 2, 2026 and October 2, 2026.
| Date | Update | Actions |
|---|---|---|
| Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - | |
| 2026-10-02 | Grant Of Employee Stock Options Under Thyrocare Employee Stock Option Scheme. | - |
| 2026-10-02 | Closure of Trading Window | - |
| 2026-09-29 | Sale Of The Entire Shareholding Held By The Company In Nueclear Healthcare Limited (A Material Wholly Owned Subsidiary) Subject To The Approval Of The Shareholders Of The Company | - |
| 2026-09-29 | Announcement under Regulation 30 (LODR)-Acquisition | - |
| 2026-09-29 | Outcome Of The Board Meeting Held On Monday September 21 2026 | - |
| 2026-09-09 | Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-09-04 | Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-04 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-01 | Communication Received From API Holdings Limited Regarding Approval Of Scheme Of Amalgamation Of Docon Technologies Private Limited With API Holdings Limited | - |
| 2026-08-19 | Disclosure under Regulation 30A of LODR | - |
| 2026-08-19 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-18 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-18 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-18 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-18 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-08-18 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-17 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-08-17 | Communication Received From Promoter Regarding Release Of Pledge On Equity Shares Of Thyrocare Technologies Limited | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹542.05, within a 52-week range of ₹349.55 to ₹1,591.90. The P/E ratio is 49.67 and the P/B ratio is 17.04, with earnings per unit of ₹10.27. Market capitalisation stands at ₹8,738.18 Cr and the dividend yield is 2.55%. The company operates in the Healthcare Services sector, in the Healthcare Service Provider industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.